[DFMO: an alternative therapeutic agent for human African trypanosomiasis].
alpha-Difluoromethyl ornithine (DFMO) irreversibly inhibits ornithine decarboxylase (ODC), an essential enzyme for the synthesis of polyamines, and results in decreased biosynthesis of putrescine and spermidine, factors necessary for cellular multiplication. Use of this chemical agent in Trypanosoma brucei brucei infected mice eradicated the parasite from circulating blood. This treatment is now being developed for use in human pathology.
D000818:Animals; D000518:Eflornithine / Q000494:pharmacology* / Q000627:therapeutic use; D014346:Trypanosoma brucei brucei / Q000187:drug effects*; D014353:Trypanosomiasis, African / Q000188:drug therapy*
D000518:Eflornithine
Le DFMO: alternative thérapeutique de la trypanosomiase humaine africaine.